Hot Investor Mandate: USA-Based Fund With China-Based Global Innovation Center Invests Broadly in All Life Science Sectors, With Recent Interest in Disease-Modification Therapies

18 Aug

A US fund invests in early-stage startups in many industries with a preference for biotech and IT technology. Typical equity investment size ranges from US$0.5-2 million in Seed to Series B stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 5+ deals in the next 12 months and can invest globally with a focus on the US.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in disease-modification therapies, diagnostics and medical devices. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market. The firm can act as either a lead or co-investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: